Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2/3 1Phase 2 1

Status

Terminated 6Active not recruiting 6Recruiting 5Completed 3Unknown 1Approved for marketing 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 4Genitourinary 2Gastrointestinal 2Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Colorectal Neoplasms 2Carcinoma, Renal Cell 2Solid Tumors 1Neoplasms 1Kidney Neoplasms 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × adagrasib × Clear all
NCT06764771 2026-06-03

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Bristol-Myers Squibb

Phase 1 Recruiting
437 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

NCT06875310 2026-06-02

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Mirati Therapeutics Inc.

Phase 3 Recruiting
630 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04613596 2026-05-20

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Mirati Therapeutics Inc.

Phase 2/3 Recruiting
626 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Mirati Therapeutics Inc.

Phase 2 Recruiting
170 enrolled
Other solid neoplasm

Solid Tumors

NCT06026410 2026-04-14

FIT-001

Kura Oncology, Inc.

Phase 1 Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡